Laryngoscopy Skills Worsen After Month Without Practice

This article originally appeared here.
Share this content:
Laryngoscopy Skills Worsen After Month Without Practice
Laryngoscopy Skills Worsen After Month Without Practice

MONDAY, Aug. 22, 2016 (HealthDay News) -- Laryngoscopy skill performance levels change after one month without practice, with worse consistency for C-MAC and A.P. Advance, according to a study published online Aug. 17 in Anaesthesia.

I. Hunter, from the Royal United Hospital in Bath in the United Kingdom, and colleagues compared the time taken to intubate the trachea of a manikin by novice medical students immediately after training and after one month with no intervening practice. The authors conducted a two-period, four-group cross-over trial to compare the Macintosh, Venner A.P. Advance with difficult airway blade, C-MAC with D-Blade, and Airtraq with wireless video-viewer.

The researchers observed no significant difference in median intubation time using the videolaryngoscopes versus the Macintosh (30 seconds) after training. Intubation time was longer using the C-MAC and A.P. Advance versus the Macintosh (41 and 30 seconds, respectively, versus 27 seconds) one month later; there was no difference for the Airtraq (27 seconds) versus the Macintosh. For each laryngoscope, skill acquisition after a brief period of learning and practice was equal; however, after one month without practice, performance levels differed. In particular, worse consistency was seen for C-MAC and A.P. Advance versus Macintosh and Airtraq.

"While the clinical significance of this is doubtful, we believe that reliable and consistent performance at laryngoscopy is desirable; for the devices that we tested, this requires regular practice," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »